Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Study protocol for a multisite randomised controlled trial of a rehabilitation intervention to reduce participation restrictions among female breast cancer survivors.  BMJ Open.  10. 2020
2019 Hypofractionated radiation in older women with breast cancer 2019
2018 Molecular determinants of post-mastectomy breast cancer recurrence.  npj Breast Cancer.  4. 2018
2018 Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancer.  Cancer.  124:475-481. 2018
2017 Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans.  PLoS ONE.  12. 2017
2016 Adherence to the Choosing Wisely Campaign Recommendations for Radiation Treatment Duration in Breast Cancer: Analysis of Medicare Data at 12 Centers in the Southeastern United States. 2016
2016 Intensity Modulated Radiation Therapy in Breast Cancer: Analysis of Medicare Data at 12 Institutions. 2016
2015 Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.  Journal of Gastrointestinal Cancer.  46:149-155. 2015
2015 PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.  Breast Cancer Research and Treatment.  150:569-579. 2015
2015 Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥3 cm 2015
2014 Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: A pilot study.  Gastrointestinal cancer research : GCR.  7:75-81. 2014
2014 The Impact of Breast Irradiation and Concurrent Trastuzumab on the Development of Early Cardiac Events: a Dosimetric Analysis.  American Journal of Breast Cancer Research.  1:9-19. 2014
2013 Accelerated partial breast irradiation for early-stage breast cancer: Controversies and current indications for use.  Current Treatment Options in Oncology.  14:51-65. 2013
2011 An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events..  Journal of Clinical Oncology.  29:121. 2011
2011 A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.  Cancer Chemotherapy and Pharmacology.  67:891-897. 2011
2011 Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapy 2011
2011 Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.  Clinical Breast Cancer.  11:312-319. 2011
2010 The importance and evolution of radiation dose in DCIS.  Current Cancer Therapy Reviews.  6:249-255. 2010
2010 Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status..  Cancer.  116:2645-2654. 2010
2010 Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer 2010
2009 EGFR FISH as a predictive factor for selection of patients with non-small cell lung cancer treated with cetuximab and chemotherapy.  American Journal of Oncology Review.  8. 2009
2008 An imrt technique to increase therapeutic ratio of breast irradiation in patients with early-stage left breast cancer: limiting second malignancies.  Medical Dosimetry.  33:71-77. 2008
2007 Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?: Commentary.  Nature Clinical Practice Oncology.  4:690-691. 2007
2007 A Dosimetric Comparison of Electronic Compensation, Conventional Intensity Modulated Radiotherapy, and Tomotherapy in Patients With Early-Stage Carcinoma of the Left Breast 2007
2005 Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer 2005
2005 Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma 2005

Principal Investigator On

Investigator On

  • Life after Breast Cancer Treatment: Racial Health Disparities and Chronic Pain in Breast Cancer Survivors  awarded by National Cancer Institute/NIH/DHHS 2020 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Optimizing Functional Recovery of Breast Cancer Survivors  awarded by DARTMOUTH-HITCHCOCK CLINIC 2019 - 2024
  • A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma  awarded by University of North Carolina at Chapel Hill 2020 - 2023
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology 2012 - 2022
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2022
  • Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  awarded by University of Pennsylvania 2019 - 2020
  • Quantifying the Burden of Breast Cancer Decision Making in Older Women  awarded by American Society of Clinical Oncology 2019 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison 2016 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by NEWLINK GENETICS, INC 2016 - 2017
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS 2016
  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953  awarded by Johns Hopkins University 2009 - 2015
  • Targeting Signal Transduction Pathways for the Treatment and Prevention of Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2012 - 2014
  • Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2011 - 2012

    • Education And Training

  • Doctor of Medicine in Radiation Oncology, University of Florida 2001
  • University of Florida/Shands Hospital, Internship 2002
  • University of Virginia Hospital, Residency 2006

    • Full Name

  • Kimberly Keene